Iradimed CORP (IRMD) Institutional Holdings & 13F Data (Q2 2026)

IRMD ranks #2818 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

IRMD is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.1% of that fund's own 13F portfolio.

IRMD is a top-conviction position for Nine Ten Capital Management LLC — at 7.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in IRMD belongs to BlackRock, Inc., but the position matters far more to Nine Ten Capital Management LLC, who has 7.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Arrowstreet Capital, Limited Partnership has added to its IRMD position for two straight quarters, increasing it by $13.1M to reach $13.8M today.

Nine Ten Capital Management LLC has trimmed its IRMD position for two straight quarters, cutting it by $17.2M while still holding $24.5M.

IRMD is down 0.5% today, but institutions show net buying of $132.3M this quarter — a divergence between today's price move and the underlying institutional flow.

IRMD posted net income of $23.1M over the trailing twelve months, and currently trades at a P/E of 48.8.

• Profitable — net income of $23.1M over the trailing twelve months
• Revenue grew 11.2% year over year
• Net income improved year over year, from $20.7M to $23.1M
• Generated $24.9M in positive operating cash flow
• Current ratio of 7.98x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.15x equity — within a conventional range